122 related articles for article (PubMed ID: 37729520)
21. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
[TBL] [Abstract][Full Text] [Related]
23. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
Fujioka M; Nakashima Y; Nakashima O; Kojiro M
Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA-II), serum a-fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non-diagnostic serum a-fetoprotein levels.
Syriha A; Pantzios S; Mandilara D; Galanis P; Stathopoulou I; Barla G; Elefsiniotis I
Cancer Med; 2024 Feb; 13(3):e6825. PubMed ID: 38361401
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
26. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.
Miyaaki H; Nakashima O; Kurogi M; Eguchi K; Kojiro M
J Gastroenterol; 2007 Dec; 42(12):962-8. PubMed ID: 18085353
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
29. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
30. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
[TBL] [Abstract][Full Text] [Related]
31. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
32. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
34. A nomogram to predict microvascular invasion in early hepatocellular carcinoma.
Li H; Li T; Hu J; Liu J
J Cancer Res Ther; 2021 Jul; 17(3):652-657. PubMed ID: 34269295
[TBL] [Abstract][Full Text] [Related]
35. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
Xu F; Zhang L; He W; Song D; Ji X; Shao J
Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
[TBL] [Abstract][Full Text] [Related]
36. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates.
Ekmen N; Akalin Ç; Akyildiz M
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):294-299. PubMed ID: 32796360
[TBL] [Abstract][Full Text] [Related]
38. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
39. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
40. Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients.
Hadi H; Wan Shuaib WMA; Raja Ali RA; Othman H
Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 36013482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
